Get started
Author

Nicole E. Carlson

BH3 Profiling Identifies Three Distinct Classes of Apoptotic Blocks to Predict Response to ABT-737 and Conventional Chemotherapeutic Agents
2007 · Jing Deng, Nicole Carlson, et al. · Cancer Cell · 528
PDF
Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1
2010 · Derek Yecies, Nicole E. Carlson, et al. · Blood · 371
Proapoptotic BH3-Only BCL-2 Family Protein BIM Connects Death Signaling from Epidermal Growth Factor Receptor Inhibition to the Mitochondrion
2007 · Jing Deng, Takeshi Shimamura, et al. · Cancer Research · 160
PDF
Aurora kinase A is a target of Wnt/β-catenin involved in multiple myeloma disease progression
2009 · Jui Dutta-Simmons, Yunyu Zhang, et al. · Blood · 110
PDF
Hydroxyquinoline-derived compounds and analoguing of selective Mcl-1 inhibitors using a functional biomarker
2013 · David J. Richard, Ryan Lena, et al. · Bioorganic & Medicinal Chemistry · 60
BH3 Profiling Discriminates Response to Cytarabine-Based Treatment of Acute Myelogenous Leukemia
2013 · William E. Pierceall, Steven M. Kornblau, et al. · Molecular Cancer Therapeutics · 33
Reversal of a potent investigational anticoagulant: Idraparinux with recombinant factor VIIa
2005 · Andrew Dao, Bertrand Tuan, et al. · The American Journal of Medicine · 11
ML311: A Small Molecule that Potently and Selectively Disrupts the Protein-Protein Interaction of Mcl-1 and Bim: A Probe for Studying Lymphoid Tumorigenesis
2013 · Thomas D. Bannister, Marcel Koenig, et al. · Europe PMC (PubMed Central) · 6
Data from BH3 Profiling Discriminates Response to Cytarabine-Based Treatment of Acute Myelogenous Leukemia
2023 · William E. Pierceall, Steven M. Kornblau, et al.
Supplementary Figures 1 - 2 from BH3 Profiling Discriminates Response to Cytarabine-Based Treatment of Acute Myelogenous Leukemia
2023 · William E. Pierceall, Steven M. Kornblau, et al.
PDF
Data from BH3 Profiling Discriminates Response to Cytarabine-Based Treatment of Acute Myelogenous Leukemia
2023 · William E. Pierceall, Steven M. Kornblau, et al.
BH3 profiling as a predictive biomarker for response to cytarabine-based treatment of acute myelogenous leukemia.
2013 · William E. Pierceall, Nicole E. Carlson, et al. · Journal of Clinical Oncology
Abstract 2466: Characterization and development of on-target Mcl-1 inhibitors; BH3 profiling provides a valuable drug discovery tool.
2013 · David J. Richard, Nicole Carlson, et al. · Cancer Research
Figure 8, Lead profiling screen results summary
2013 · Thomas D. Bannister, Marcel Koenig, et al.
Figure 5, Primary target, biochemical assay (Mcl-1)
2013 · Thomas D. Bannister, Marcel Koenig, et al.
Figure 6, Cell-based assays
2013 · Thomas D. Bannister, Marcel Koenig, et al.
Figure 7, NCI60 growth inhibition
2013 · Thomas D. Bannister, Marcel Koenig, et al.
Works count: 18
Citation count: 1,279
H-index: 7
I10-index: 7
Year
Topic
Type